Remote exercise training for people with heart failure and preserved ejection fraction
Tests remotely monitored bicycle exercise training in adults with heart failure and preserved ejection fraction.
Plain-language title generated from the registry record
Registry title: Remote Rehabilitation in Patients With HFpEF (PATRON-HF)
Key facts
- Where
- Chrzanów, Katowice, and Tychy, PolandSee the 3 sites
Where in Poland
- Małopolska Cardiovascular Center, Polish-American Heart Clinic in ChrzanówChrzanów, PolandTaking people
- Telcor Medical Center ScanmedKatowice, PolandTaking people
- Polish-American Heart Clinics X Department of Invasive Cardiology, Electrophysiology and Electrostimulation in TychyTychy, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- American Heart of Poland
- Trial code
- NCT07918209
- Record updated
- 5 November 2026
- Original description
Heart failure with preserved ejection fraction (HFpEF) is characterized by typical symptoms of heart failure, structural and functional cardiac abnormalities, and elevated serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), despite preserved left ventricular ejection fraction. Typical symptoms of HFpEF include reduced exercise tolerance, exertional dyspnea, paroxysmal nocturnal dyspnea, and orthopnea.Read full original descriptionShow less
A Multicenter, Randomized Research Experiment to Compare the Standard Care Model to a Rehabilitation Strategy Based on Remotely Monitored, Regular Training Using a Bicycle Ergometer in Patients With Heart Failure With Preserved Ejection Fraction (PATRON-HF)
Heart failure with preserved ejection fraction (HFpEF) is characterized by typical symptoms of heart failure, structural and functional cardiac abnormalities, and elevated serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), despite preserved left ventricular ejection fraction. Typical symptoms of HFpEF include reduced exercise tolerance, exertional dyspnea, paroxysmal nocturnal dyspnea, and orthopnea.
It is estimated that approximately 35 million people worldwide suffer from HFpEF, including approximately 3 million patients in the United States. The exact number of patients with HFpEF remains unknown; however, the prevalence of the disease is increasing. Risk factors for HFpEF include obesity, arterial hypertension, atrial fibrillation, diabetes mellitus, dyslipidemia, and advanced age. Patients with HFpEF are hospitalized an average of 1.4 times per year, and the annual mortality rate is approximately 15%. To date, the most effective approach to the management of HFpEF has been the control of comorbidities, including diabetes mellitus, arterial hypertension, coronary artery disease, and obesity.
Remote rehabilitation (RR) has already become an established component of modern cardiology. It is widely used in developed countries, and its popularity continues to increase. Its main advantages include reduced costs for both patients and healthcare payers compared with traditional, center-based rehabilitation. In addition, for patients living far from rehabilitation centers or those with limited access to transportation, remote rehabilitation provides a solution to improve access to care.
The efficacy and safety of remote rehabilitation have been demonstrated in cardiac patients with coronary artery disease and in patients with heart failure with reduced ejection fraction (HFrEF). However, to date, the safety and efficacy of remote rehabilitation in patients with HFpEF have not been sufficiently investigated. Therefore, the aim of the proposed study is to assess the safety and efficacy of remote rehabilitation in patients with HFpEF.
Inclusion: Presence of at least one of the following symptoms: dyspnea, orthopnea, paroxysmal nocturnal dyspnea, reduced exercise tolerance, fatigue, prolonged recovery time after exercise; Presence of at least one of the following findings on physical examination: elevated jugular venous pressure, hepatojugular reflux, audible third heart sound (S3), laterally displaced apical impulse; Presence of at least one of the following findings on transthoracic echocardiography: enlarged left atrium and/or left ventricle, E/e' ≥13, e' <9 cm/s; NT-proBNP >250 pg/mL or >600 pg/mL in patients with atrial fibrillation; Left ventricular ejection fraction (LVEF) ≥50%; Age >40 years; Ability to perform exercise on a bicycle ergometer with ECG monitoring; No contraindications to coronary angiography.
Exclusion: History of myocardial infarction, stroke, transient ischemic attack, or another major cardiovascular event within the previous 60 days; Microvascular angina, defined as exertional anginal chest pain in the absence of stenosis in the epicardial coronary arteries; Atrial fibrillation or atrial flutter with a heart rate >110 bpm at the first visit; Acute decompensated heart failure; Chronic pulmonary disease requiring home oxygen therapy and/or oral corticosteroid therapy; Pulmonary hypertension; Active malignancy or suspected malignancy; Alcohol use disorder or illicit drug use; Allergy to the adhesive or material used in the electrodes required for telemonitoring; Left ventricular ejection fraction (LVEF) <50%; Liver transaminase levels >3 times the upper limit of the local reference range; Chronic kidney disease with eGFR <20 mL/min/1.73 m²; Hemoglobin <9 mg/dL; Diagnosed cardiomyopathy, including infiltrative, storage, hypertrophic, or cardiomyopathy caused by a known reversible etiology; Constrictive pericarditis; Blood pressure >180/110 mmHg; In the investigator's opinion, the patient is unable to participate in the clinical trial.